Endo Health To Pay $225M For Generics Company

Law360, New York (August 28, 2013, 1:20 PM EDT) -- A generic drug unit of Endo Health Solutions plans to scoop up Florida-based Boca Pharmacal for $225 million, an all-cash deal that signals the start of a series of transactions aimed at leveraging growth against hefty risks linked to the Pennsylvania pharmaceutical giant's fight over key patents.

Endo said Wednesday that its subsidiary Qualitest has inked a deal with privately held Boca, a specialty generics company that will boost the unit's offerings with niche products in categories such as capsules, semi-solids, solutions and suspensions, according to...
To view the full article, register now.